View in EDS HTML Full Text PDF Full Text

Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling.

Saved in:
Bibliographic Details
Title: Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling.
Authors: Thomas A; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA. anish.thomas@nih.gov., Takahashi N; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Oplustil O'Connor L; AstraZeneca, Cambridge, UK., Redon CE; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Mohindroo C; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Sciuto L; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Pongor L; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Schmidt KT; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Steinberg SM; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Aladjem MI; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., Figg WD; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA., O'Connor MJ; AstraZeneca, Cambridge, UK., Pommier Y; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.
Source: Nature communications [Nat Commun] 2025 Oct 27; Vol. 16 (1), pp. 9457. Date of Electronic Publication: 2025 Oct 27.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41145467
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Thomas+A%22">Thomas A</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA. anish.thomas@nih.gov.<br /><searchLink fieldCode="AU" term="%22Takahashi+N%22">Takahashi N</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22Oplustil+O'Connor+L%22">Oplustil O'Connor L</searchLink>; AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Redon+CE%22">Redon CE</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22Mohindroo+C%22">Mohindroo C</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22Sciuto+L%22">Sciuto L</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22Pongor+L%22">Pongor L</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22Schmidt+KT%22">Schmidt KT</searchLink>; Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Steinberg+SM%22">Steinberg SM</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22Aladjem+MI%22">Aladjem MI</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22Figg+WD%22">Figg WD</searchLink>; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.<br /><searchLink fieldCode="AU" term="%22O'Connor+MJ%22">O'Connor MJ</searchLink>; AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Pommier+Y%22">Pommier Y</searchLink>; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2025 Oct 27; Vol. 16 (1), pp. 9457. <i>Date of Electronic Publication: </i>2025 Oct 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41145467
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-025-64509-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 9457
    Titles:
      – TitleFull: Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Thomas A
      – PersonEntity:
          Name:
            NameFull: Takahashi N
      – PersonEntity:
          Name:
            NameFull: Oplustil O'Connor L
      – PersonEntity:
          Name:
            NameFull: Redon CE
      – PersonEntity:
          Name:
            NameFull: Mohindroo C
      – PersonEntity:
          Name:
            NameFull: Sciuto L
      – PersonEntity:
          Name:
            NameFull: Pongor L
      – PersonEntity:
          Name:
            NameFull: Schmidt KT
      – PersonEntity:
          Name:
            NameFull: Steinberg SM
      – PersonEntity:
          Name:
            NameFull: Aladjem MI
      – PersonEntity:
          Name:
            NameFull: Figg WD
      – PersonEntity:
          Name:
            NameFull: O'Connor MJ
      – PersonEntity:
          Name:
            NameFull: Pommier Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 10
              Text: 2025 Oct 27
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1